Advertisement
MGNX vs ZVRA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGNX is a Hold and ZVRA is a Hold.
Momentum Indicator for MGNX turns positive, indicating new upward trend
MGNX saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 78 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on October 21, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.393) is normal, around the industry mean (2.973). P/E Ratio (-16.500) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ZVRA sees MACD Histogram just turned negative
ZVRA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 41 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZVRA as a result. In 75 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
ZVRA moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ZVRA crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZVRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for ZVRA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZVRA's RSI Oscillator exited the oversold zone, 23 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 67 cases where ZVRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +5.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZVRA advanced for three days, in 230 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ZVRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 29 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. ZVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZVRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.818) is normal, around the industry mean (2.973). P/E Ratio (10.760) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (10.667) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (438.009).
MGNX | ZVRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 86 | |
SMR RATING 1..100 | 97 | 29 | |
PRICE GROWTH RATING 1..100 | 47 | 62 | |
P/E GROWTH RATING 1..100 | 23 | 84 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MGNX's Valuation (86) in the Biotechnology industry is in the same range as ZVRA (91) in the null industry. This means that MGNX’s stock grew similarly to ZVRA’s over the last 12 months.
ZVRA's Profit vs Risk Rating (86) in the null industry is in the same range as MGNX (100) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to MGNX’s over the last 12 months.
ZVRA's SMR Rating (29) in the null industry is significantly better than the same rating for MGNX (97) in the Biotechnology industry. This means that ZVRA’s stock grew significantly faster than MGNX’s over the last 12 months.
MGNX's Price Growth Rating (47) in the Biotechnology industry is in the same range as ZVRA (62) in the null industry. This means that MGNX’s stock grew similarly to ZVRA’s over the last 12 months.
MGNX's P/E Growth Rating (23) in the Biotechnology industry is somewhat better than the same rating for ZVRA (84) in the null industry. This means that MGNX’s stock grew somewhat faster than ZVRA’s over the last 12 months.
| MGNX | ZVRA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 75% |
| Advances ODDS (%) | 1 day ago 85% | 3 days ago 82% |
| Declines ODDS (%) | 9 days ago 84% | 1 day ago 75% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MGNX’s FA Score shows that 1 FA rating(s) are green while ZVRA’s FA Score has 1 green FA rating(s).
- MGNX’s FA Score: 1 green, 4 red.
- ZVRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MGNX’s TA Score shows that 5 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).
- MGNX’s TA Score: 5 bullish, 4 bearish.
- ZVRA’s TA Score: 4 bullish, 6 bearish.
Price Growth
MGNX (@Biotechnology) experienced а +7.72% price change this week, while ZVRA (@Biotechnology) price change was +0.58% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
MGNX is expected to report earnings on Nov 11, 2026.
ZVRA is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement